Aprea Therapeutics, Inc. (APRE) is a publicly traded company in the Unknown sector. Across all available filings, 31 corporate insiders have executed 164 transactions totaling $93.5M, demonstrating a bearish sentiment with -$34.2M in net insider flow. The most recent transaction on Dec 10, 2025 involved a purchase of 5,000 shares valued at $5.8K.
No significant insider buying has been recorded for APRE in the recent period.
No significant insider selling has been recorded for APRE in the recent period.
Based on recent SEC filings, insider sentiment for APRE is bearish with an Insider Alignment Score of 32/100 and a net flow of -$34.2M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Aprea Therapeutics, Inc. (APRE) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 31 insiders are actively trading APRE stock, having executed 164 transactions in the past 90 days. The most active insider is Scott M. Rocklage (Executive), who has made 10 transactions totaling $20.0M.
Get notified when executives and directors at APRE file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | P. Hamill John | Executive | Purchase | 5,000 | $1.17 | $5.8K | |
| Dec 10, 2025 | Duey Marc | Executive | Purchase | 21,459 | $1.17 | $25.1K | |
| Jun 20, 2024 | Duey Marc | Executive | Award | 1,045 | $N/A | $0 | |
| Jun 20, 2024 | Grissinger Michael | Executive | Award | 1,045 | $N/A | $0 | |
| Jun 20, 2024 | B. Henneman John III | Executive | Award | 1,045 | $N/A | $0 | |
| Jun 20, 2024 | Peters Richard | Executive | Award | 1,045 | $N/A | $0 | |
| Jun 20, 2024 | Pamukcu Rifat | Executive | Award | 1,045 | $N/A | $0 | |
| Jun 20, 2024 | R. Seizinger Bernd | Executive | Award | 1,045 | $N/A | $0 | |
| May 1, 2024 | Q. Mirza Nadeem | Executive | Award | 6,730 | $N/A | $0 | |
| Mar 28, 2024 | Gilad Oren | Executive | Award | 6,725 | $N/A | $0 | |
| Mar 28, 2024 | P. Hamill John | Executive | Award | 3,365 | $N/A | $0 | |
| Mar 13, 2024 | Gilad Oren | Executive | Purchase | 2,000 | $7.29 | $14.6K | |
| Mar 13, 2024 | B. Henneman John III | Executive | Purchase | 6,860 | $7.29 | $50.0K | |
| Mar 13, 2024 | R. Seizinger Bernd | Executive | Purchase | 6,860 | $7.29 | $50.0K | |
| Mar 13, 2024 | P. Hamill John | Executive | Purchase | 1,010 | $7.29 | $7.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 27 | $63.9M | 68.0% |
Purchase(P) | 29 | $29.6M | 31.5% |
Payment(F) | 12 | $262.9K | 0.3% |
Exercise(M) | 7 | $188.7K | 0.2% |
Award(A) | 48 | $5.3K | 0.0% |
Conversion(C) | 23 | $0 | 0.0% |
Other(J) | 18 | $0 | 0.0% |
Insider selling pressure at Aprea Therapeutics, Inc. has increased, with 31 insiders executing 164 transactions across all time. Total sales of $63.9M significantly outpace purchases of $29.6M, resulting in a net outflow of $34.2M. This selling activity appears largely discretionary, which may warrant closer attention from investors.